Pleural mesothelioma
MONDO:0003308A neoplasm that arises from the mesothelial cells of the pleura. The primary cause is exposure to asbestos. The major histologic variants are the epithelioid malignant mesothelioma, desmoplastic malignant mesothelioma, and sarcomatoid malignant mesothelioma. Patients present with persistent cough and shortness of breath.
Also known as: mesothelioma of pleura, mesothelioma of the pleura, pleura mesothelioma, pleural mesothelioma, pleural mesothelioma (disease), benign pleural mesothelioma, pleural mesothelioma (disease), benign
1517 clinical trials for this condition and its sub-types, 28 tagged with Pleural mesothelioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pleural mesothelioma
-
Malignant pleural mesothelioma 71 trials · 75 incl. sub-types
2 sub-types
- Pleural epithelioid mesothelioma 8 trials
- Pleural sarcomatoid mesothelioma 2 trials
-
Pleural adenomatoid tumor 0 trials
-
Can a new nucleotide analogue boost cancer treatment?
Disease control Stopped earlyThis trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…
Phase 1/2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Engineered immune cells take aim at Mesothelin-Positive tumors
Disease control Stopped earlyThis trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…
Phase 1/2 • Sponsor: TCR2 Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Experimental lung cancer combo trial ends early
Disease control Stopped earlyThis phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
A simple breath test could spot mesothelioma years earlier
Diagnosis Stopped earlyThis study explores whether chemicals in a person's breath, called volatile organic compounds, can serve as early warning signs of pleural mesothelioma in people who have been exposed to asbestos. Researchers will also check if a blood marker, SMRP, adds to the breath test's accu…
Sponsor: Henry Ford Health System • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC